In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933

M. A. Alaoui-Jamali, R. L. Schecter, Y. M. Rustum, M. G. Centurioni, S. Lehnert, G. Batist

Research output: Contribution to journalArticlepeer-review


The effectiveness of a calcium antagonist analog Ro11-2933 to modulate doxorubicin (DOX) response in DOX-sensitive (WT) and -resistant (DOXr, 200- fold) cell lines was investigated and compared to verapamil (VP) in vitro and in vivo in rats bearing mammary carcinoma using equivalent nontoxic doses. In vitro exposure to a nontoxic concentration of Ro11-2933 (2 μM) normalizes the DOX accumulation defect observed in DOXr cells, increases DOX-induced DNA single-strand breaks and effectively sensitizes DOXr cells to DOX. Ten μM VP was required to obtain an effect equivalent to that seen with 2 μM Ro11- 2933. Intravenous administration of DOX at 5 mg/kg to the rat bearing the DOXr tumors has no significant therapeutic effect on tumor growth (P > .5), whereas it was found effective in inhibiting the growth of WT tumors (P <.05). Ro11-2933 or VP administered alone has no significant effect on tumor growth as compared to a saline-treated group (P > .1). Combination of Ro11- 2933 with DOX effectively inhibits DOXr tumor growth as compared to DOX alone. Combination of DOX with VP was found less effective than Ro11-2933 and the results were not statistically significant from DOX treatment alone (P > .5). Our data demonstrate that Ro11-2933 is well tolerated after i.v. administration and an effective modulator of DOX resistance in a solid tumor model.

Original languageEnglish
Pages (from-to)1299-1304
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Issue number3
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933'. Together they form a unique fingerprint.

Cite this